These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 30929843)

  • 1. The Metabolic Landscape of Prostate Cancer.
    Giunchi F; Fiorentino M; Loda M
    Eur Urol Oncol; 2019 Feb; 2(1):28-36. PubMed ID: 30929843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence.
    Ettinger SL; Sobel R; Whitmore TG; Akbari M; Bradley DR; Gleave ME; Nelson CC
    Cancer Res; 2004 Mar; 64(6):2212-21. PubMed ID: 15026365
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cellular metabolism in pancreatic cancer as a tool for prognosis and treatment (Review).
    Zuzčák M; Trnka J
    Int J Oncol; 2022 Aug; 61(2):. PubMed ID: 35730611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic Vulnerabilities of Prostate Cancer: Diagnostic and Therapeutic Opportunities.
    Zadra G; Loda M
    Cold Spring Harb Perspect Med; 2018 Oct; 8(10):. PubMed ID: 29229664
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Bruzzone C; Loizaga-Iriarte A; Sánchez-Mosquera P; Gil-Redondo R; Astobiza I; Diercks T; Cortazar AR; Ugalde-Olano A; Schäfer H; Blanco FJ; Unda M; Cannet C; Spraul M; Mato JM; Embade N; Carracedo A; Millet O
    J Proteome Res; 2020 Jun; 19(6):2419-2428. PubMed ID: 32380831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Functional genomic studies reveal the androgen receptor as a master regulator of cellular energy metabolism in prostate cancer.
    Gonthier K; Poluri RTK; Audet-Walsh É
    J Steroid Biochem Mol Biol; 2019 Jul; 191():105367. PubMed ID: 31051242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metastasis initiating cells in primary prostate cancer tissues from transurethral resection of the prostate (TURP) predicts castration-resistant progression and survival of prostate cancer patients.
    Li Q; Li Q; Nuccio J; Liu C; Duan P; Wang R; Jones LW; Chung LW; Zhau HE
    Prostate; 2015 Sep; 75(12):1312-21. PubMed ID: 25990623
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Model-driven discovery of long-chain fatty acid metabolic reprogramming in heterogeneous prostate cancer cells.
    Marín de Mas I; Aguilar E; Zodda E; Balcells C; Marin S; Dallmann G; Thomson TM; Papp B; Cascante M
    PLoS Comput Biol; 2018 Jan; 14(1):e1005914. PubMed ID: 29293497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel selenonucleoside suppresses tumor growth by targeting Skp2 degradation in paclitaxel-resistant prostate cancer.
    Byun WS; Jin M; Yu J; Kim WK; Song J; Chung HJ; Jeong LS; Lee SK
    Biochem Pharmacol; 2018 Dec; 158():84-94. PubMed ID: 30292755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Profiling Prostate Cancer Therapeutic Resistance.
    Wade CA; Kyprianou N
    Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29562686
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of microRNA signature and potential pathway targets in prostate cancer.
    Moustafa AA; Ziada M; Elshaikh A; Datta A; Kim H; Moroz K; Srivastav S; Thomas R; Silberstein JL; Moparty K; Salem FE; El-Habit OH; Abdel-Mageed AB
    Exp Biol Med (Maywood); 2017 Mar; 242(5):536-546. PubMed ID: 27903835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biological Evolution of Castration-resistant Prostate Cancer.
    Davies A; Conteduca V; Zoubeidi A; Beltran H
    Eur Urol Focus; 2019 Mar; 5(2):147-154. PubMed ID: 30772358
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS-Driven Metabolic Rewiring Reveals Novel Actionable Targets in Cancer.
    Pupo E; Avanzato D; Middonti E; Bussolino F; Lanzetti L
    Front Oncol; 2019; 9():848. PubMed ID: 31544066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SREBF1 Activity Is Regulated by an AR/mTOR Nuclear Axis in Prostate Cancer.
    Audet-Walsh É; Vernier M; Yee T; Laflamme C; Li S; Chen Y; Giguère V
    Mol Cancer Res; 2018 Sep; 16(9):1396-1405. PubMed ID: 29784665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell metabolomics identify regulatory pathways and targets of magnoline against prostate cancer.
    Sun H; Zhang AH; Liu SB; Qiu S; Li XN; Zhang TL; Liu L; Wang XJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Dec; 1102-1103():143-151. PubMed ID: 30391728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NMR-based metabolomics studies of human prostate cancer tissue.
    Lima AR; Pinto J; Bastos ML; Carvalho M; Guedes de Pinho P
    Metabolomics; 2018 Jun; 14(7):88. PubMed ID: 30830350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolomic profiling for the identification of novel diagnostic markers and therapeutic targets in prostate cancer: an update.
    Lucarelli G; Loizzo D; Ferro M; Rutigliano M; Vartolomei MD; Cantiello F; Buonerba C; Di Lorenzo G; Terracciano D; De Cobelli O; Bettocchi C; Ditonno P; Battaglia M
    Expert Rev Mol Diagn; 2019 May; 19(5):377-387. PubMed ID: 30957583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting ACLY sensitizes castration-resistant prostate cancer cells to AR antagonism by impinging on an ACLY-AMPK-AR feedback mechanism.
    Shah S; Carriveau WJ; Li J; Campbell SL; Kopinski PK; Lim HW; Daurio N; Trefely S; Won KJ; Wallace DC; Koumenis C; Mancuso A; Wellen KE
    Oncotarget; 2016 Jul; 7(28):43713-43730. PubMed ID: 27248322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid Uptake Is an Androgen-Enhanced Lipid Supply Pathway Associated with Prostate Cancer Disease Progression and Bone Metastasis.
    Tousignant KD; Rockstroh A; Taherian Fard A; Lehman ML; Wang C; McPherson SJ; Philp LK; Bartonicek N; Dinger ME; Nelson CC; Sadowski MC
    Mol Cancer Res; 2019 May; 17(5):1166-1179. PubMed ID: 30808729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.